79 related articles for article (PubMed ID: 18416442)
1. Joint spatial survival modeling for the age at diagnosis and the vital outcome of prostate cancer.
Zhou H; Lawson AB; Hebert JR; Slate EH; Hill EG
Stat Med; 2008 Aug; 27(18):3612-28. PubMed ID: 18416442
[TBL] [Abstract][Full Text] [Related]
2. Patient- and area-level predictors of prostate cancer among South Carolina veterans: a spatial analysis.
Georgantopoulos P; Eberth JM; Cai B; Emrich C; Rao G; Bennett CL; Haddock KS; Hébert JR
Cancer Causes Control; 2020 Mar; 31(3):209-220. PubMed ID: 31975155
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian hierarchical modeling approach for studying the factors affecting the stage at diagnosis of prostate cancer.
Zhou H; Lawson AB; Hebert JR; Slate EH; Hill EG
Stat Med; 2008 Apr; 27(9):1468-89. PubMed ID: 17708511
[TBL] [Abstract][Full Text] [Related]
4. Bayesian Parametric Accelerated Failure Time Spatial Model and its Application to Prostate Cancer.
Zhang J; Lawson AB
J Appl Stat; 2011 Mar; 38(2):591-603. PubMed ID: 21475617
[TBL] [Abstract][Full Text] [Related]
5. Soil zinc content, groundwater usage, and prostate cancer incidence in South Carolina.
Wagner SE; Burch JB; Hussey J; Temples T; Bolick-Aldrich S; Mosley-Broughton C; Liu Y; Hebert JR
Cancer Causes Control; 2009 Apr; 20(3):345-53. PubMed ID: 18949566
[TBL] [Abstract][Full Text] [Related]
6. Spatially-explicit survival modeling with discrete grouping of cancer predictors.
Onicescu G; Lawson AB; Zhang J; Gebregziabher M; Wallace K; Eberth JM
Spat Spatiotemporal Epidemiol; 2019 Jun; 29():139-148. PubMed ID: 31128623
[TBL] [Abstract][Full Text] [Related]
7. Spatial extended hazard model with application to prostate cancer survival.
Li L; Hanson T; Zhang J
Biometrics; 2015 Jun; 71(2):313-22. PubMed ID: 25521422
[TBL] [Abstract][Full Text] [Related]
8. The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Shoaibi A; Rao GA; Cai B; Rawl J; Hébert JR
Ann Epidemiol; 2016 Jan; 26(1):36-42.e1-2. PubMed ID: 26611771
[TBL] [Abstract][Full Text] [Related]
9. A Bayesian normal mixture accelerated failure time spatial model and its application to prostate cancer.
Wang S; Zhang J; Lawson AB
Stat Methods Med Res; 2016 Apr; 25(2):793-806. PubMed ID: 23117407
[TBL] [Abstract][Full Text] [Related]
10. A spatial assessment of prostate cancer mortality-to-incidence ratios among South Carolina veterans: 1999-2015.
Georgantopoulos P; Eberth JM; Cai B; Rao G; Bennett CL; Emrich CT; Haddock KS; Hébert JR
Ann Epidemiol; 2021 Jul; 59():24-32. PubMed ID: 33836289
[TBL] [Abstract][Full Text] [Related]
11. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
[TBL] [Abstract][Full Text] [Related]
12. Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
Shoaibi A; Rao GA; Cai B; Rawl J; Haddock KS; Hébert JR
Prostate; 2017 Feb; 77(2):173-184. PubMed ID: 27699819
[TBL] [Abstract][Full Text] [Related]
13. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
[TBL] [Abstract][Full Text] [Related]
14. Geographic variation in prostate cancer survival in New South Wales.
Yu XQ; Luo Q; Smith DP; O'Connell DL; Baade PD
Med J Aust; 2014 Jun; 200(10):586-90. PubMed ID: 24882490
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian piecewise survival cure rate model for spatially clustered data.
Hurtado Rúa SM; Dey DK
Spat Spatiotemporal Epidemiol; 2019 Jun; 29():149-159. PubMed ID: 31128624
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis.
Antwi S; Everson TM
Cancer Epidemiol; 2014 Aug; 38(4):435-41. PubMed ID: 24802851
[TBL] [Abstract][Full Text] [Related]
17. Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort.
Vis AN; Roemeling S; Reedijk AM; Otto SJ; Schröder FH
Eur Urol; 2008 Jan; 53(1):91-8. PubMed ID: 17583416
[TBL] [Abstract][Full Text] [Related]
18. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017.
Siegel DA; O'Neil ME; Richards TB; Dowling NF; Weir HK
MMWR Morb Mortal Wkly Rep; 2020 Oct; 69(41):1473-1480. PubMed ID: 33056955
[TBL] [Abstract][Full Text] [Related]
19. Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis.
Husson O; van Steenbergen LN; Koldewijn EL; Poortmans PM; Coebergh JW; Janssen-Heijnen ML
BJU Int; 2014 Nov; 114(5):691-7. PubMed ID: 24131890
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.
Krimphove MJ; Cole AP; Fletcher SA; Harmouch SS; Berg S; Lipsitz SR; Sun M; Nabi J; Nguyen PL; Hu JC; Kibel AS; Choueiri TK; Kluth LA; Trinh QD
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):125-136. PubMed ID: 30171227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
